NCT03503643 is a clinical trial of Hemigland Cryoablation in Prostate Cancer, sponsored by Jonsson Comprehensive Cancer Center.

Who is sponsoring NCT03503643?

NCT03503643 is sponsored by Jonsson Comprehensive Cancer Center.

What drugs are being tested in NCT03503643?

Interventions in NCT03503643: Hemigland Cryoablation.

What condition does NCT03503643 study?

NCT03503643 studies Prostate Cancer, Prostate Adenocarcinoma, Prostate Disease.

Is NCT03503643 still recruiting?

NCT03503643 is currently enrolling by invitation. Last updated 13 May 2025.

Last reviewed 2025-05-13 · How we verify

NCT03503643

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hemi-Gland Cryoablation for Prostate Cancer at UCLA

ENROLLING BY INVITATION Last updated 13 May 2025

What this trial tests

trial testing Hemigland Cryoablation in Prostate Cancer in 100 participants. Enrolling by invitation.

Timeline

14 September 2017

Primary endpoint
31 December 2024

31 December 2026

Quick facts

Lead sponsor	Jonsson Comprehensive Cancer Center
Status	ENROLLING BY INVITATION
Study type	OBSERVATIONAL
Enrollment	100
Start date	14 September 2017
Primary completion	31 December 2024
Estimated completion	31 December 2026
Sites	1 location across United States

Drugs / interventions tested

Hemigland Cryoablation

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →
Prostate Adenocarcinoma — all drugs for Prostate Adenocarcinoma →
Prostate Disease — all drugs for Prostate Disease →

Sponsor

Jonsson Comprehensive Cancer Center — full company profile →

Who can join

Eligibility, male only, with Prostate Cancer or Prostate Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective data collection of men who are electing to undergo prostate hemi-gland cryoablation. The purpose of this observational research study is to investigate the localized treatment of prostate cancer using hemi-gland cryoablation. UCLA patients undergoing hemi-gland cryoablation are a unique cohort compared to prior research because all patients at UCLA have had a pre-treatment multi-parametric MRI and Ultrasound fusion targeted biopsy; they will be followed in a similar fashion. This results in more precise assessment of a target region of cancer for ablation which may, in turn, result in improved clinical outcomes.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Cryotherapy for partial gland ablation of prostate cancer: Oncologic and safety outcomes.
Aker MN, Brisbane WG, Kwan L, Gonzalez S, et al · · 2023 · cited 23× · PMID 36775929 · DOI 10.1002/cam4.5692
Hemigland Cryoablation of Clinically Significant Prostate Cancer: Intermediate-Term Followup via Magnetic Resonance Imaging Guided Biopsy.
Chuang R, Kinnaird A, Kwan L, Sisk A, et al · · 2020 · cited 18× · PMID 32985924 · DOI 10.1097/ju.0000000000001133
Genomic Biomarker for Prostate Cancer Focal Therapy: Post Hoc Assessment of a Phase II Clinical Trial.
Weiner AB, Proudfoot JA, Aker M, Cardenas M, et al · · 2025 · cited 2× · PMID 40961406 · DOI 10.1200/po-25-00535
Evolution of Active Surveillance of Prostate Cancer: Impact of Magnetic Resonance Imaging, Magnetic Resonance Imaging-Guided Biopsy, and Focal Therapy.
Martin SC, Gonzalez S, Kwan L, Delfin M, et al · · 2025 · cited 1× · PMID 40257918 · DOI 10.1097/ju.0000000000004559

Verify or expand the search:

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other Jonsson Comprehensive Cancer Center trials

Trials by the same sponsor.

NCT07229339 — Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT06448286 — PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glio · Phase 3 · not yet recruiting
NCT07517211 — A Prospective Study of Physical Function in Adults Who Receive Systemic Therapy for Stage I-III Gastroesophageal Cancer, · not yet recruiting
NCT07191717 — Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Resi · Phase 2 · not yet recruiting
NCT07468903 — Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03503643 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jonsson Comprehensive Cancer Center
Last refreshed: 13 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03503643.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing